plerixafor
Sign in to saveAlso known as AMD 3100, AMD3100, bicyclam JM-2987, JM 3100, Mozobil®
Plerixafor, sold under the brand name Mozobil, is an immunostimulant used to mobilize hematopoietic stem cells in cancer patients into the bloodstream. The stem cells are then extracted from the blood and transplanted back to the patient. The drug was developed by AnorMED, which was subsequently bought by Genzyme.
Wikidata facts
- Mass
- 502.447
Show 4 more facts
- chemical formula
- C₂₈H₅₄N₈
- canonical SMILES
- C1CNCCNCCCN(CCNC1)CC2=CC=C(C=C2)CN3CCCNCCNCCCNCC3
- defined daily dose
- 16.8
- Commons category
- Plerixafor
Sources (7)
via Wikidata · CC0
~7 min read
Article
17 sectionsContents
- Medical uses
- Contraindications
- Pregnancy and lactation
- Adverse effects
- Interactions
- Pharmacology
- Mechanism of action
- Pharmacokinetics
- Chemistry
- Synthesis
- History
- Society and culture
- Research
- Anti-cancer properties
- Use in stem cell research
- Neurologic
- References
Plerixafor, sold under the brand name Mozobil, is an immunostimulant used to mobilize hematopoietic stem cells in cancer patients into the bloodstream. The stem cells are then extracted from the blood and transplanted back to the patient. The drug was developed by AnorMED, which was subsequently bought by Genzyme.
==Medical uses== Peripheral blood stem cell mobilization, which is important as a source of hematopoietic stem cells for transplantation, is generally performed using granulocyte colony-stimulating factor (G-CSF), but is ineffective in around 15 to 20% of patients. Combination of G-CSF with plerixafor increases the percentage of persons that respond to the therapy and produce enough stem cells for transplantation. The drug is approved for patients with lymphoma and multiple myeloma.
Available in 11 languages
via Wikidata sitelinks · CC0